Adaptive Biotechnologies(DE:1HM)
€26.66+2.11 (+13.79%)
DE:1HM
Adaptive Biotechnologies financials statements
€26.66
At close:+2.11 (+13.79%)
Adaptive Biotechnologies (1HM) Ratios
3 Followers
Adaptive Biotechnologies Ratios
DE:1HM's free cash flow for Q3 2026 was $7.68M. For the 2026 fiscal year, DE:1HM's free cash flow was decreased by $-1.93M and operating cash flow was $9.61M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.34 | 2.89 | 4.66 | 5.12 | 3.54 |
| Quick Ratio | 3.23 | 2.81 | 4.50 | 4.99 | 3.37 |
| Cash Ratio | 0.78 | 0.49 | 0.74 | 0.82 | 1.22 |
| Solvency Ratio | -0.14 | -0.42 | -0.58 | -0.46 | -0.61 |
| Operating Cash Flow Ratio | -0.51 | -0.97 | -1.78 | -1.68 | -1.69 |
| Short-Term Operating Cash Flow Coverage | -3.39 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 12.45M | $ -53.14M | $ 57.33M | $ 169.63M | $ 83.51M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.55 | 0.17 | 0.15 | 0.13 | 0.12 |
| Debt-to-Equity Ratio | 1.28 | 0.44 | 0.32 | 0.23 | 0.19 |
| Debt-to-Capital Ratio | 0.56 | 0.31 | 0.24 | 0.19 | 0.16 |
| Long-Term Debt-to-Capital Ratio | 0.47 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 2.34 | 2.66 | 2.14 | 1.85 | 1.53 |
| Debt Service Coverage Ratio | -1.18 | -11.12 | -13.72 | -41.34 | 0.00 |
| Interest Coverage Ratio | -4.85 | -14.04 | -16.45 | -47.24 | 0.00 |
| Debt to Market Cap | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 1.93 | 0.69 | 0.78 | 0.79 | 0.80 |
| Net Debt to EBITDA | -7.04 | -0.32 | -0.18 | -0.10 | 0.14 |
| Profitability Margins | |||||
| Gross Profit Margin | 74.24% | 59.72% | 55.63% | 68.75% | 68.06% |
| EBIT Margin | -17.21% | -82.71% | -124.21% | -105.84% | -134.31% |
| EBITDA Margin | -10.78% | -71.95% | -111.16% | -94.55% | -125.27% |
| Operating Profit Margin | -20.62% | -90.83% | -133.33% | -108.03% | -135.39% |
| Pretax Profit Margin | -21.47% | -89.18% | -132.32% | -108.13% | -134.31% |
| Net Profit Margin | -21.48% | -89.12% | -132.29% | -108.03% | -134.30% |
| Continuous Operations Profit Margin | -21.47% | -89.18% | -132.32% | -108.13% | -134.31% |
| Net Income Per EBT | 100.07% | 99.94% | 99.98% | 99.91% | 99.99% |
| EBT Per EBIT | 104.09% | 98.18% | 99.24% | 100.09% | 99.20% |
| Return on Assets (ROA) | -11.60% | -29.57% | -34.07% | -23.37% | -22.45% |
| Return on Equity (ROE) | -27.19% | -78.68% | -73.04% | -43.13% | -34.32% |
| Return on Capital Employed (ROCE) | -13.51% | -36.83% | -39.61% | -26.80% | -25.81% |
| Return on Invested Capital (ROIC) | -13.09% | -36.00% | -38.98% | -26.48% | -25.65% |
| Return on Tangible Assets | -15.18% | -38.25% | -41.94% | -27.39% | -26.05% |
| Earnings Yield | -2.41% | -18.07% | -31.84% | -18.39% | -5.26% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.50 | 4.29 | 4.48 | 4.63 | 8.87 |
| Payables Turnover | 11.03 | 9.92 | 9.79 | 7.16 | 14.91 |
| Inventory Turnover | 7.27 | 8.54 | 5.23 | 4.01 | 2.56 |
| Fixed Asset Turnover | 3.71 | 1.90 | 1.42 | 1.13 | 0.89 |
| Asset Turnover | 0.54 | 0.33 | 0.26 | 0.22 | 0.17 |
| Working Capital Turnover Ratio | 1.40 | 0.70 | 0.44 | 0.50 | 0.34 |
| Cash Conversion Cycle | 83.52 | 91.06 | 113.90 | 119.04 | 159.30 |
| Days of Sales Outstanding | 66.37 | 85.11 | 81.39 | 78.90 | 41.17 |
| Days of Inventory Outstanding | 50.23 | 42.74 | 69.80 | 91.10 | 142.61 |
| Days of Payables Outstanding | 33.08 | 36.79 | 37.29 | 50.95 | 24.48 |
| Operating Cycle | 116.60 | 127.85 | 151.19 | 170.00 | 183.78 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.30 | -0.65 | -1.08 | -1.29 | -1.37 |
| Free Cash Flow Per Share | -0.32 | -0.67 | -1.16 | -1.41 | -1.81 |
| Dividend Paid and CapEx Coverage Ratio | -15.54 | -25.99 | -14.61 | -11.25 | -3.12 |
| Capital Expenditure Coverage Ratio | -15.54 | -25.99 | -14.61 | -11.25 | -3.12 |
| Operating Cash Flow Coverage Ratio | -0.16 | -1.07 | -1.58 | -1.70 | -1.72 |
| Operating Cash Flow to Sales Ratio | -0.17 | -0.53 | -0.92 | -0.99 | -1.25 |
| Free Cash Flow Yield | -1.99% | -11.20% | -23.61% | -18.40% | -6.46% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -41.64 | -5.56 | -3.14 | -5.44 | -19.00 |
| Price-to-Sales (P/S) Ratio | 8.90 | 4.93 | 4.15 | 5.88 | 25.52 |
| Price-to-Book (P/B) Ratio | 11.26 | 4.35 | 2.29 | 2.35 | 6.52 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -50.34 | -8.93 | -4.24 | -5.44 | -15.48 |
| Price-to-Operating Cash Flow Ratio | -53.58 | -9.27 | -4.53 | -5.92 | -20.43 |
| Price-to-Earnings Growth (PEG) Ratio | 0.65 | 0.18 | -0.06 | 0.17 | -0.50 |
| Enterprise Value Multiple | -89.60 | -7.18 | -3.92 | -6.32 | -20.23 |
| Enterprise Value | 2.67B | 924.08M | 741.19M | 1.11B | 3.91B |
| EV to EBITDA | -89.60 | -7.18 | -3.92 | -6.32 | -20.23 |
| EV to Sales | 9.65 | 5.16 | 4.35 | 5.97 | 25.34 |
| EV to Free Cash Flow | -54.63 | -9.35 | -4.44 | -5.53 | -15.37 |
| EV to Operating Cash Flow | -58.15 | -9.71 | -4.74 | -6.02 | -20.29 |
| Tangible Book Value Per Share | 0.69 | 0.54 | 1.28 | 2.37 | 3.40 |
| Shareholders’ Equity Per Share | 1.44 | 1.38 | 2.14 | 3.26 | 4.30 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 1.83 | 1.22 | 1.18 | 1.30 | 1.10 |
| Net Income Per Share | -0.39 | -1.08 | -1.56 | -1.40 | -1.48 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.25 | 1.08 | 1.07 | 1.02 | 1.00 |
| Research & Development to Revenue | 0.34 | 0.58 | 0.72 | 0.76 | 0.92 |
| SG&A to Revenue | 0.60 | 0.88 | 0.49 | 0.48 | 0.48 |
| Stock-Based Compensation to Revenue | 0.19 | 0.30 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.77 | 0.60 | 0.69 | 0.92 | 0.93 |
Currency in USD
